Breast Cancer Core Needle Biopsy Market To Reach $1.15 Billion By 2030

Breast Cancer Core Needle Biopsy Market Growth & Trends

The global breast cancer core needle biopsy market is expected to reach USD 1.15 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 4.9% from 2023 to 2030. The market growth is primarily propelled by factors such as the increasing prevalence of breast cancer, the widespread recommendations for regular mammography screenings, rising awareness among individuals, and extensive research studies conducted in this field. These factors collectively contribute to the rising demand and adoption of breast cancer core needle biopsy procedures, paving the way for significant growth in the coming years.

Additionally, continuous advancements in imaging technologies and biopsy techniques contribute to the expansion of the industry. There is a growing recognition of the crucial role that early detection and diagnosis play in improving patient outcomes. Core needle biopsies offer distinct advantages over traditional open surgical biopsies, including reduced invasiveness, quicker recovery time, and cost-effectiveness.

As the demand for early detection and diagnosis continues to rise, the market for breast cancer core needle biopsy is expected to witness significant growth. A recent example of innovative research in this field involves the use of contrast-mammography-guided breast biopsies that utilize MRI technology for lesion visualization, as demonstrated by researchers at the IMIM (Hospital del Mar Medical Research Institute) in Spain, in 2022 with the findings published in the journal European Radiology.

The COVID-19 pandemic has both challenged and opened new opportunities in the breast cancer core needle biopsy market. Delays in non-essential procedures have led to a decrease in diagnosis rate and demand for core needle biopsies. However, the pandemic has emphasized the importance of early detection, leading healthcare providers to prioritize screenings and biopsies, resulting in a resurgence in demand.

 Request a free sample copy or view report summary: Breast Cancer Core Needle Biopsy Market Report

Breast Cancer Core Needle Biopsy Market Report Highlights

• By technology, the ultrasound-based breast biopsy segment dominated the market in 2022 due to its advantages over other biopsy technologies in terms of disease diagnosis. Further, increasing technological advancements are also expected to accelerate segment growth.

• By end-use, hospitals & diagnostic laboratories segment held the largest market share in 2022, due to the increasing adoption of breast cancer biopsy instruments in hospitals along with growing demand for novel diagnostics technologies.

• North America held a strong regional position in the market in 2022 owing to its highly developed healthcare infrastructure and presence of technologically advanced companies.

Breast Cancer Core Needle Biopsy Market Segmentation

Grand View Research has segmented global breast cancer core needle biopsy market based on technology, end-use, and region.

Breast Cancer Core Needle Biopsy Technology Scope Outlook (Revenue, USD Million, 2018 - 2030)

• MRI-based Breast Biopsy

• Ultrasound-based Breast Biopsy

• Mammography-based (Stereotactic) Breast Biopsy

• CT-based Breast Biopsy

• Other Image Based Breast Biopsy

Breast Cancer Core Needle Biopsy End-use Scope Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Diagnostic Laboratories

• Pharmaceutical & Biotechnology Companies

• Academic & Research Institutes

Breast Cancer Core Needle Biopsy Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• Australia

• Thailand

• South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Breast Cancer Core Needle Biopsy Market

• Intact Medical Corporation

• Ethicon Surgical Technologies

• Gallini SRL

• Leica Biosystems Nussloch GmbH

• Hologic, Inc.

• Argon Medical Devices

• Encapsule Medical Devices LLC

• Cook Medical Incorporated

• Becton, Dickinson and Company

• C.R. Bard, Inc.